MLTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
MoonLake Immunotherapeutics
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$9.75+0.20 (+2.09%)
Close on Oct 19, 2026
- Market cap
- $720.67M
- P/E (TTM)
- –
- Dividend yield
- –
MoonLake Immunotherapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | MoonLake Immunotherapeutics | Industry median |
|---|---|---|
| Market Cap | $829.79M | $164.85M |
| Enterprise Value | $292.79M | $87.06M |
| PB Ratio | 1.94 | 2.03 |
| P/TBV Ratio | 1.94 | 2.31 |
Income (trailing twelve months)
| Measure | MoonLake Immunotherapeutics | Industry median |
|---|---|---|
| Operating Income | -$268.34M | -$21.44M |
| Net Income | -$263.67M | -$22.46M |
| EBITDA | -$265.10M | -$16.91M |
| EPS (Diluted) | -$3.84 | -$0.83 |
Returns
| Measure | MoonLake Immunotherapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -67.4% | -53.1% |
| Return on Assets (ROA) | -51.0% | -41.0% |
| Return on Capital Employed (ROCE) | -50.8% | -37.8% |
Balance sheet
| Measure | MoonLake Immunotherapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $537.00M | $62.42M |
| Net Cash (Debt) | $537.00M | $15.68M |
| Net Cash Per Share | $6.31 | $0.66 |
| Equity (Book Value) | $428.20M | $48.79M |
| Book Value Per Share | $5.03 | $1.36 |
| Tangible Book Value | $428.20M | $23.06M |
| Working Capital | $524.65M | $75.77M |
Financial position
| Measure | MoonLake Immunotherapeutics | Industry median |
|---|---|---|
| Current Ratio | 12.56 | 3.30 |
| Quick Ratio | 11.83 | 2.39 |
| Interest Coverage | -26.59 | -7.12 |
Cash flow (trailing twelve months)
| Measure | MoonLake Immunotherapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$225.18M | -$12.35M |
| Capital Expenditures | $0 | -$1.06M |
| Free Cash Flow | -$225.18M | -$20.28M |
| FCF Per Share | -$2.65 | -$0.42 |
Efficiency
| Measure | MoonLake Immunotherapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$2.03M | -$703.34K |
| Employee Count | 130 | 74 |
Dividends and yields
| Measure | MoonLake Immunotherapeutics | Industry median |
|---|---|---|
| Earnings Yield | -31.8% | -22.7% |
| FCF Yield | -27.1% | -9.07% |
Shares
| Measure | MoonLake Immunotherapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 85,106,700 | 58,179,650 |
| Shares Change (YoY) | 9.52% | 11.1% |
| Float | 34,105,500 | 49,173,100 |
| Shares Held by Insiders | 59.9% | 11.6% |
| Shares Held by Institutions | 86.3% | 59.4% |
Taxes
| Measure | MoonLake Immunotherapeutics | Industry median |
|---|---|---|
| Income Tax | $1.08M | $91.50K |
Scores
| Measure | MoonLake Immunotherapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 1.52 | -0.24 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from MoonLake Immunotherapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.